Insulet Corp.

Is Insulet Corp. technically bullish or bearish?

As of October 24, 2025, Insulet Corp. shows a mildly bullish trend with mixed technical signals, having outperformed the S&P 500 year-to-date and over the past year, but underperformed over the longer 3, 5, and 10-year periods.

As of 24 October 2025, the technical trend for Insulet Corp. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages and a bullish indication from Bollinger Bands on both weekly and monthly time frames. However, the weekly MACD and KST are mildly bearish, and the monthly RSI is bearish, indicating mixed signals. <BR><BR>In terms of performance, Insulet has outperformed the S&P 500 year-to-date with a return of 22.92% compared to the S&P 500's 15.47%, and over the past year, it has returned 35.05% versus the S&P 500's 16.90%. However, over the longer term, it has underperformed the S&P 500 significantly in the 3-year, 5-year, and 10-year periods.

Is Insulet Corp. overvalued or undervalued?

As of August 7, 2025, Insulet Corp. is considered very expensive due to high valuation ratios compared to peers, despite recent short-term stock performance outperforming the S&P 500, indicating potential unsustainability in the long run.

As of 7 August 2025, the valuation grade for Insulet Corp. has moved from fair to very expensive, indicating a significant shift in its market perception. The company appears overvalued based on its current valuation ratios, including a P/E ratio of 51, a Price to Book Value of 16.49, and an EV to EBITDA of 51.48. In comparison to peers, Insulet's P/E ratio is notably higher than ResMed, Inc. at 37.73 and Zimmer Biomet Holdings, Inc. at 29.65, which further supports the conclusion of overvaluation.<BR><BR>Recent stock performance shows that while Insulet has outperformed the S&P 500 year-to-date with a return of 27.75% compared to 12.22%, its longer-term returns over three and five years have lagged behind the index, with returns of 30.79% and 48.21% respectively, versus 70.41% and 96.61% for the S&P 500. This trend suggests that despite short-term gains, the company's elevated valuation may not be sustainable in the long run.

How big is Insulet Corp.?

As of Jun 18, Insulet Corp. has a market capitalization of $21.42 billion, with recent net sales of $2.20 billion and a net profit of $402.20 million.

Market Cap: As of Jun 18, Insulet Corp. has a market capitalization of 21,421.42 million, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Insulet Corp. reported net sales of 2,198.90 million and a net profit of 402.20 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1,211.60 million and total assets of 3,087.70 million.

What does Insulet Corp. do?

Insulet Corporation develops and sells the OmniPod Insulin Management System for insulin-dependent diabetes. As of March 2025, it reported net sales of $569 million and a market cap of approximately $21.42 billion.

Overview: <BR>Insulet Corporation is engaged in the development, manufacturing, and sale of the OmniPod Insulin Management System, an insulin delivery system for people with insulin-dependent diabetes, and operates within the Pharmaceuticals & Biotechnology industry in the mid-cap market segment.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 569 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 35 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 21,421.42 Million (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 51.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.31 <BR>Return on Equity: 32.41% <BR>Price to Book: 16.10<BR><BR>Contact Details: <BR>Address: 100 Nagog Park, ACTON MA: 01720-3440 <BR>Tel: ['1 978 6007000', '1 978 6007717'] <BR>Fax: 1 978 6000120 <BR>Website: https://www.myomnipod.com

Should I buy, sell or hold Insulet Corp.?

Who are in the management team of Insulet Corp.?

As of March 2022, the management team of Insulet Corp. includes Timothy Scannell (Independent Chairman), Shacey Petrovic (President and CEO), and several independent directors: Wayne Frederick, Sally Crawford, John Fallon, James Hollingshead, and Jessica Hopfield. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Insulet Corp. includes the following individuals:<BR><BR>- Mr. Timothy Scannell, who serves as the Independent Chairman of the Board.<BR>- Ms. Shacey Petrovic, who is the President, Chief Executive Officer, and Director.<BR>- Dr. Wayne Frederick, who is a Director.<BR>- Ms. Sally Crawford, who is an Independent Director.<BR>- Dr. John Fallon, who is an Independent Director.<BR>- Dr. James Hollingshead, who is an Independent Director.<BR>- Dr. Jessica Hopfield, who is an Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.